The Italian pilot external quality assessment program for cystic fibrosis sweat test

2016 ◽  
Vol 49 (7-8) ◽  
pp. 601-605 ◽  
Author(s):  
Marco Salvatore ◽  
Giovanna Floridia ◽  
Annalisa Amato ◽  
Federica Censi ◽  
Claudio Carta ◽  
...  
Author(s):  
Marco Salvatore ◽  
Annalisa Amato ◽  
Giovanna Floridia ◽  
Federica Censi ◽  
Gianluca Ferrari ◽  
...  

(1) Background: Diagnostic testing for cystic fibrosis (CF) is based on a sweat chloride test (SCT) considering the appropriate signs and symptoms of the disease and results of a gene mutation analysis. In 2014, the Istituto Superiore di Sanità (ISS) established a pilot Italian external quality assessment program for CF SCT (Italian EQA-SCT), which is now a third party service carried out by the ISS. (2) Methods: The ongoing scheme is prospective, enrollment is voluntary, and the payment of a fee is required. Results are shared through a dedicated web-facility. Assessment covers the analysis, interpretation, and reporting of results. (3) Results: Thirteen, fifteen, sixteen, and fifteen different laboratories, respectively, participated from 2015 to 2016 and from 2018 to 2019 in the Italian EQA-SCT scheme. Eleven different laboratories participated each year in all four rounds of the Italian EQA-SCT. (4) Conclusions: The overall results obtained from the laboratories participating constantly clearly show that their qualitative and quantitative performance improved significantly. This is due to the opportunity—after receiving the EQA results—to constantly review their performance and address any inconsistencies. We firmly believe that participation in the EQA program will improve the quality of participating laboratories and that EQA participation should become mandatory as a fundamental requirement for laboratory accreditation.


1994 ◽  
Vol 9 (1) ◽  
pp. 43-47 ◽  
Author(s):  
G.C. Zucchelli ◽  
A. Pilo ◽  
M.R. Chiesa ◽  
S. Masini ◽  
A. Clerico

Immunoassays of the tumor markers CA 19.9, CA125 and CA 15.3 are generally acknowledged to be a useful tool in the management of cancer patients. As a consequence, many methods developed by different companies are now commercially available. However, discrepancies have been described in the results of marker determinations even when the same monoclonal antibody was used. An external quality assessment (EQA) was carried out; starting from 1989 about 110 laboratories participated; since December 1991 the program was linked with the interlaboratory program Oncocheck organized by the Service de Radiopharmacie et Radioanalyse, University of Lyon. At present more than 200 laboratories of many European countries are involved: cumulatively 47 quality control samples have been prepared and sent to the participants. This manuscript is a report on data collected for CA 19.9, CA 125, and CA 15.3.


2019 ◽  
Vol 65 (03/2019) ◽  
Author(s):  
Falin He ◽  
Wei Wang ◽  
Chaowen Yu ◽  
Kun Zhong ◽  
Shuai Yuan ◽  
...  

2005 ◽  
Vol 66 (8) ◽  
pp. 20
Author(s):  
Raja Rajalingam ◽  
Marie Lau ◽  
Zeying Du ◽  
Arlene Locke ◽  
John Muramoto ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document